Preoperative or induction chemotherapy with docetaxel, cisplatin, plus 5-fluorouracil (DCF) is a promising regimen for advanced esophageal cancer. However, the DCF regimen is associated with a high risk of severe neutropenia or febrile neutropenia (FN).
cinoma of the esophagus were recruited. They were treated with the DCF therapy on days 1-5, with pegfilgrastim given on day 3. Primary endpoint was the occurrence of grade 4 neutropenia. Secondary endpoints included the incidence of FN, grade 3 neutropenia, dose delays/reductions, antitumor effect, and safety. Between July 2016 and December 2018, 23 patients were enrolled. The incidence of grade 4 neutropenia was 8.7% (95% confidence interval 1.1%-28.0%). No patient experienced FN. Of the 19 patients who received two cycles of DCF, one required a dose reduction/treatment delay due to hematological toxicity in the second treatment cycle. No serious adverse events, considered relevant to pegfilgrastim, were observed. This is the first prospective study that showed an efficacious dosing schedule of pegfilgrastim for preventing hematological toxicity during DCF therapy. The results might be generalized to other similar regimens where continuous infusions of 5-fluorouracil are used. 
| INTRODUC TI ON
Esophageal cancer is the sixth leading cause of cancer-related death worldwide, and its incidence is increasing globally. 1 Although esophagectomy is the curative treatment for patients with locally advanced esophageal cancer, the results are unsatisfactory with a 5year survival rate of <40%. 2 To improve treatment outcomes, several neoadjuvant therapies have been recommended. Both preoperative chemotherapy and chemoradiotherapy improve overall survival compared to surgery alone. [3] [4] [5] In Western countries, neoadjuvant chemoradiotherapy is recommended as standard preoperative treatment, whereas in most Eastern countries, including Japan, neoadjuvant chemotherapy is recommended as a preoperative treatment for locally advanced esophageal cancer. However, the superiority of neoadjuvant chemotherapy or chemoradiotherapy remains controversial. Radiotherapy is expected to improve local control, whereas chemotherapy has the potential to eliminate micrometastases, thus, improving systemic control. In Japan, transthoracic esophagectomy with regional lymphadenectomy has achieved better local control. 6 Therefore, systemic control with intensive neoadjuvant chemotherapy is considered more important to improve the survival of patients with locally advanced esophageal cancers.
Currently, neoadjuvant chemotherapy with CF is recommended as standard treatment for locally advanced esophageal cancers in Japan. However, overall survival with this treatment remains unsatisfactory. 7 In this context, strategies to reinforce neoadjuvant chemotherapy by adding docetaxel to CF (DCF) have been explored to improve overall survival. Hara and colleagues conducted a feasibility study of the DCF regimen for locally advanced esophageal cancers and showed highly promising antitumor activity (overall response rate = 64.3%, pathological complete response = 17%) and severe myelotoxicity reactions (≥grade 3 neutropenia = 83.3%). 8 Although DCF might be promising for locally advanced esophageal cancers, the adverse event of severe myelotoxicity was consistently reported in the literature. The incidence of ≥grade 3 neutropenia and febrile neutropenia (FN) reached 66.6% and 22.9%, respectively. 9 Thus, although DCF has a highly promising antitumor activity, it has a very high risk of severe neutropenia or FN, which is a safety concern as preoperative treatment.
Primary prophylaxis with pegfilgrastim, a long-acting pegylated form of G-CSF, is recommended for the prevention of FN in patients receiving high-risk chemotherapy regimens such as DCF. According to the guidelines, 10,11 pegfilgrastim should be given at least 24 hours after the completion of chemotherapy (ie, 1-3 days [American Society of Clinical Oncology, ASCO] or 1-4 days [National Comprehensive Cancer Network, NCCN] after chemotherapy). However, there is no prospective study on the DCF regimen that validates the efficacy and safety of pegfilgrastim in the prevention of FN, and there are only two retrospective studies. 12, 13 One study was on head and neck cancer and the other was our study on esophageal cancer. Our previous retrospective study evaluated the efficacy of giving pegfilgrastim on day 7, which was 24 hours after the completion of DCF therapy. ANC nadir was observed from day 7, and the incidence rates of ≥grade 3 neutropenia and FN were 50.0% and 22.7%, respectively. 13 Thus, timing (day 7) of the dose was not appropriate as the ANC nadir appeared early. Until now, the optimal dosing schedule of pegfilgrastim along with regimens involving continuous infusions of 5-fluorouracil remains unclear. No prospective trial has evaluated the timing of giving prophylactic G-CSF along with DCF therapy. Therefore, we conducted this prospective study to assess the efficacy and safety of early dosing (day 3) of pegfilgrastim during DCF therapy for patients with advanced squamous cell carcinoma of the esophagus.
| PATIENTS AND ME THODS

| Study design and patients
We conducted a single-arm, phase II study to evaluate the efficacy and safety of early dosing (day 3) of pegfilgrastim during DCF therapy for patients with squamous cell carcinoma of the esophagus.
Participants with pathologically diagnosed primary squamous cell carcinoma of the esophagus were identified at University Hospital, Kyoto Prefectural University of Medicine and selected based on the following eligibility criteria.
| Key inclusion criteria
Histologically confirmed squamous cell carcinoma of the esophagus; clinical stage II, III or IV (International Union Against Cancer TNM classification system, 7th edition); patients over 20 years old who could be treated with DCF therapy without dose reduction; no prior history of systemic chemotherapy or radiotherapy; ECOG performance status 0 or 1; and adequate organ function (leukocyte count ≥4000 and <12 000/μL, neutrophil count ≥1500/μL, hemoglobin level ≥10.0 g/dL, platelet count ≥100 000/μL, AST and ALT ≤100 IU/L, total bilirubin ≤1.5 mg/dL, serum creatinine ≤1.5 mg/dL, creatinine clearance ≥60 mL/min).
| Key exclusion criteria
Malignancies other than carcinoma in situ or mucosal carcinoma; 
| Treatment procedures
Chemotherapy consisted of an infusion of docetaxel (70 mg/m 2 per day) and cisplatin (70 mg/m 2 per day) on day 1, and continuous infusions of 5-fluorouracil (750 mg/m 2 per day) on days 1-5 (DCF: 70/70/750). The regimen was repeated every 3 weeks. Pegfilgrastim was given as a single s.c. injection at a dose of 3.6 mg on day three in each cycle. Prophylactic oral antibiotics (ie, levofloxacin) on days 5-9 in each cycle were allowed if deemed necessary by physicians.
| Assessments
Blood samples were collected for complete blood count and serum chemistry on days 1, 3, 7, 8, 9, 10, and 14 of each cycle. FN is defined as an ANC lower than 1000/μL at a temperature of 38°C or higher. Safety was assessed using the incidence of adverse events.
Severity of all adverse events was graded in line with the Common
Terminology Criteria for Adverse Events v 4.0 (CTCAE). Tumor response was assessed using computed tomography (CT) scans in the third or fourth week of the second cycle based on the RECIST ver- 
| Endpoints and statistical methods
Primary objective of the present study was to estimate the incidence of grade 4 neutropenia in cycle one. Secondary objectives were to estimate the incidence of FN and grade 3 neutropenia, and the depth of the ANC nadir in cycle one and the incidence of delayed chemotherapy and dose reduction of cytotoxic drugs in cycle two.
Evaluation of the antitumor effect after two cycles of chemotherapy and a safety assessment during chemotherapy were also included as secondary objectives.
In the present study, we expected the incidence of grade 4 neutropenia during DCF therapy along with pegfilgrastim to be lower than that without giving prophylactic G-CSF, and that the proportion of grade 4 neutropenia would be lower than that from the previous Japanese studies (63%-82%). 15, 16 A minimum sample size of 21 was required for one-sided α of 0.1 and β of 0.1, with an expected 25% incidence of grade 4 neutropenia and a threshold incidence of 55%. Assuming 10% dropout cases, the target sample size was 24 patients in total. Confidence intervals for all proportions were estimated assuming binomial distribution. All statistical analyses were carried out using SPSS software (version 20) for Windows (IBM Corporation).
| RE SULTS
| Patients
Between July 2016 and January 2019, 23 eligible patients were enrolled in this study. Patient characteristics are shown in Table 1 .
Sixteen patients were males and seven were females. Median age of all patients was 62 years (range: 44-75). Most patients had an ECOG performance status of 0 or 1. Overall, 19 patients received two cycles of DCF therapy, and four patients discontinued the subsequent second cycle of DCF therapy. Two patients were switched to doublet chemotherapy as a result of severe toxicities (ie, hematopoietic and gastrointestinal toxicities or nephrotoxicity), and two were switched to chemoradiotherapy because of the lack of efficacy. Finally, 19 of 23 patients underwent esophagectomy (Figure 1 ).
| Efficacy of pegfilgrastim
Incidence of grade 4 neutropenia in cycle 1 was 8.7% (2/23, 95% CI: 1.1%-28.0%), and the confidence interval (80% CI: 2.3%-21.5%) corresponding to one-sided α of 0.1 showed that the incidence was statistically significantly lower than the threshold value of 55%. Six 
| Safety
Overall adverse events excluding neutropenia and FN are listed in 
| Treatment outcome
| D ISCUSS I ON
As DCF therapy is associated with a high risk of infection, FN, and severe neutropenia, giving primary prophylactic G-CSF is recommended to lower the risks. However, the guidelines do not recommend a detailed dosing plan for G-CSF in the course of continuous chemotherapy for several days. According to the guidelines, 10, 11 G-CSF should be given 24 hours after the completion of chemotherapy due to the likelihood of increased sensitivity of rapidly dividing myeloid cells to cytotoxic chemotherapy and, paradoxically, increased risks of hematological toxicity. There is a lack of data on the concomitant use of G-CSF and chemotherapy, and the optimal dosing schedule of pegfilgrastim remained unclear along with regimens that involved continuous infusions of 5-fluorouracil such as the DCF regimen. In the present study, we showed that giving pegfilgrastim on day 3 reduced the incidence of grade 4 neutropenia (8.7%), FN (0%), and the occurrence of dose delay or reduction of chemotherapy.
In other words, giving concomitant pegfilgrastim and 5-fluorouracil did not increase hematological toxicity, and this protocol is safe and effective for the prevention of severe neutropenia and FN. This Based on the theoretical concern that the stimulation of bone marrow progenitors by G-CSF might increase the pool of precursors vulnerable to cell cycle-specific chemotherapy, giving G-CSF is recommended 24 hours after chemotherapy. However, several reports showed that a simultaneous dose of pegfilgrastim and cytotoxic chemotherapy is feasible and safe in different chemotherapy regimens. [17] [18] [19] [20] As for DCF therapy, a retrospective study investigated the efficacy and safety of early dosage of G-CSF in patients with head and neck cancer. 12 This study was conducted to compare early dosage of G-CSF (pegfilgrastim on day 3 or filgrastim from day 3 to day 11) during chemotherapy versus pegfilgrastim on day 7 in patients treated with DCF. The incidence of grade In the present study, the frequency of grade 4 neutropenia was 8.7% (80% CI: 2.3%-21.5%), which was significantly lower than the prespecified threshold of 55%, and was also much lower than the reported frequencies (63%-82%) for DCF therapy for esophageal cancer without prophylactic dosage of pegfilgrastim. 15, 16 The frequency of grade 3 or higher neutropenia was 26.1%, which was lower than the previous reports (67%-83%). 8, 9 In terms of FN, it is reported that the incidence usually reached 22.9% in DCF therapy without preventive measures such as prophylactic use of antibiotics. 9 However, it should be taken into account that giving pegfilgrastim may have attenuated the antitumor effects of DCF therapy.
The small number of patients and a short follow-up period (42 days) are major limitations of our study. In addition, we used pegfilgrastim at a dose of 3.6 mg, which is approved by the Japanese healthcare system. However, pegfilgrastim is usually given at a dose of 6.0 mg in other countries. Therefore, it is not clear whether the study results are applicable to the 6.0-mg pegfilgrastim treatment protocol. In this study, prophylactic antibiotics were given in all cases, and this could have potentially confounded the effect of pegfilgrastim on FN development. Recently, giving broad-spectrum antibiotics has been reported to impair the anticancer effects of chemotherapy. 21, 22 Moreover, primary antibioprophylaxis therapy for chemotherapy-induced FN is not recommended by the European Organization for Research and Treatment of Cancer (EORTC). 23 Therefore, it is necessary to examine the effect of pegfilgrastim without antibiotics.
In conclusion, the present study is the first prospective clinical trial showing that giving early pegfilgrastim as primary prophylaxis in DCF therapy is effective and safe in reducing the risk of severe neutropenia and FN. Our observations should be further confirmed by comparative trials with sufficient sample size and a longer followup period. In the future, the impact on efficacy should be carefully evaluated in large-scale studies.
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